Morphotek is committed to developing novel classes of biological-based products to treat cancer, inflammatory and infectious diseases. The company believes that monoclonal antibodies (mAbs), which represent the fastest growing segment of the biopharmaceutical market, hold the greatest promise to specifically treat and eradicate human disease.

Morphotek’s mission is to develop superior mAbs and biological therapies optimized for pharmacological activity using our suite of proprietary technologies. Morphotek will continue to achieve these goals by hiring and collaborating with the best talent in industry and academia, and empowering them to achieve extraordinary results.

As a wholly owned subsidiary of Eisai, Ltd., Morphotek has retained an independent workplace while benefiting from the ability to collaborate and actively exchange ideas with Eisai scientists in laboratories around the world.

Morphotek’s therapeutic antibodies and proprietary discovery technologies, combined with Eisai’s research and commercial infrastructure, will help Eisai meet its human health care goal of satisfying unmet medical needs and increasing benefits to cancer patients around the world.